PolyNovo's full-year 2025 results showed strong growth, with net profit after tax increasing by 151% to $13.2 million and commercial sales rising 28.9% to $118.6 million

PolyNovo's full-year (FY) results for the period ending June 30, 2025, show significant financial growth, with total revenue increasing 23.3% to A$129.19 million and net profit after tax (NPAT) surging 151.2% to A$13.21 million compared to the prior year. This strong performance was driven by a significant rise in commercial sales and the successful launch of the NovoSorb MTX in the U.S.  

https://www.linkedin.com/posts/polynovo-biomaterials-pty-ltd-_fy25-full-year-results-activity-7365593771121545216-4F6g/

Exhibitor Data Sheet